Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9493040rdf:typepubmed:Citationlld:pubmed
pubmed-article:9493040lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C2936173lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0520997lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:9493040lifeskim:mentionsumls-concept:C0205087lld:lifeskim
pubmed-article:9493040pubmed:issue1lld:pubmed
pubmed-article:9493040pubmed:dateCreated1998-4-27lld:pubmed
pubmed-article:9493040pubmed:abstractTextThe presence of late potentials (LP) after myocardial infarction (MI) is related to an occluded infarct-related coronary artery (IRA). However, the effects of the signal-averaged electrocardiogram (SAECG) of systemic thrombolysis are contradicting. Reperfusion in the IRA is more frequently observed after primary percutaneous transluminal coronary angioplasty (PTCA) than after systemic thrombolysis. The aim of this prospective study was to compare the prevalence of LP in survivors of acute MI treated with either systemic thrombolysis or primary PTCA.lld:pubmed
pubmed-article:9493040pubmed:languageenglld:pubmed
pubmed-article:9493040pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9493040pubmed:citationSubsetIMlld:pubmed
pubmed-article:9493040pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9493040pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9493040pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9493040pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9493040pubmed:statusMEDLINElld:pubmed
pubmed-article:9493040pubmed:monthJanlld:pubmed
pubmed-article:9493040pubmed:issn0046-5968lld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:BruneGGlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:UslenghiEElld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:RossettiGGlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:FerreroVVlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:SteffeninoGGlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:RaccaEElld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:VadoAAlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:DellavalleAAlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:RibichiniFFlld:pubmed
pubmed-article:9493040pubmed:authorpubmed-author:MenardiEElld:pubmed
pubmed-article:9493040pubmed:issnTypePrintlld:pubmed
pubmed-article:9493040pubmed:volume28lld:pubmed
pubmed-article:9493040pubmed:ownerNLMlld:pubmed
pubmed-article:9493040pubmed:authorsCompleteYlld:pubmed
pubmed-article:9493040pubmed:pagination3-11lld:pubmed
pubmed-article:9493040pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:meshHeadingpubmed-meshheading:9493040-...lld:pubmed
pubmed-article:9493040pubmed:year1998lld:pubmed
pubmed-article:9493040pubmed:articleTitlePrevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.lld:pubmed
pubmed-article:9493040pubmed:affiliationDivisione di Cardiologia, Ospedale S. Croce, Cuneo.lld:pubmed
pubmed-article:9493040pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9493040pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9493040pubmed:publicationTypeComparative Studylld:pubmed